How big is the problem
Around 1% of the global population, nearly 80 million, suffers from epilepsy. A third of cases do not respond to available medication, and these have been our focus in early trials. Current treatments range from long-term medication to vagus nerve stimulation and brain surgery, each of which has disadvantages, ranging from damaging long-term side effects to surgical risk.